This book observes the idea of race as a false representation for the cause of disease. Race-based medicine, an emerging field in pharmacology, aims to create a specialty market based on racial groups. Within this market, the drug Bi Dil set a precedent in this area of medicine targeting African Americans as its first racial group. Consequently, selecting African Americans as a “starter group” led to ethical questions regarding the motive behind race-based medicine within the context of the larger treatment of blacks in American medical history. This book therefore links medicine and American eugenics, examines race-based medicine’s influence on the perception of the black body, traces the influence of Bi Dil’s approval on the resurgence of race-based medicine, and assesses the black church’s response to race-based medicine using black liberation theology as a means to social justice.
表中的内容
Chapter 1 Introduction.- Chapter 2 Race-Based Medicine.- Chapter 3 Maleficence toward the Minority Patient.- Chapter 4 Research, Race, and Profit.- Chapter 5 Black Theology and Reconciliation.- Chapter 6 Conclusion.- Bibliography.
关于作者
Dr. Kirk A. Johnson teaches at Seton Hall University and Berkeley College in New Jersey, US. He is a member of the American Society of Bioethics and Humanities and The New York Academy of Medicine. He serves as a member of the Atlantic Health Systems Bioethics Committee and was formerly Assistant Director of the Medical Humanities program at Drew University in Madison, New Jersey, US.